Themis Medicare Ltd gets add on approval for drug VIRALEX®

Themis Medicare Ltd. (Themis), a Pharmaceutical company headquartered in Mumbai with a legacy of over 50 years of making new treatment options available, announced the add on approval for drug VIRALEX® by the Drug Controller General of India (DCGI) for treatment of Influenza and other Acute Viral Respiratory Infections (AVRI), Mucocutaneous herpes, Genital wart and Subacute Sclerosing Panencephalitis (SSPE).

VIRALEX® (Inosine Pranobex) is an immunomodulatory agent with broad spectrum antiviral properties. Earlier VIRALEX® was approved by DCGI for restricted emergency use in Covid 19 patients based on the results of two Randomized controlled trials (RCT) in 499 Indian patients.

Inosine Pranobex is in clinical use for >50 years since its first approval internationally. It is currently marketed in >70 countries across the world including many advance countries for the treatment of several viral diseases with established efficacy and safety profile.

VIRALEX® strengthens the immune system through modulation of T-cell proliferation, T-cell function, natural killer cell activity, phagocytosis, and also by modulating certain cytokines, and enhances body's immune response to various viral infections.

NK cells are the first line defense against viral infections. VIRALEX® enhances human NK cell cytotoxicity in two ways by increasing NK cell numbers and facilitating identification of virus-infected cell by NK cells by NKG2D ligand expression.

Based on world wide experience, the drug offer clinical benefits to the patients and address the unmet medical need in management of various viral infections, especially influenza and AVRI.

According to Themis, VIRALEX® is manufactured at an EU-GMP-certified facility with the highest safety standards and stringent manufacturing protocols in place, and the medication is available on prescription in the form of a 500 mg tablet at an affordable price.

Speaking at the release, Dr. Sachin Patel, Managing Director& CEO of Themis Medicare Ltd. said, "Our endeavor has always been to develop medicines that address unmet medical needs and make healthcare far, far more effective for patient benefits".

With a strong R&D backup, skilled domestic & export teams, and state-of-theart manufacturing sites, the endeavour at Themis has always been to support the medical fraternity with solutions for therapeutic gaps, like VIRALEX® for treating Viral Infections... and still counting!

Shares of Themis Medicare Limited was last trading in BSE at Rs. 829.85 as compared to the previous close of Rs. 807.05. The total number of shares traded during the day was 458 in over 96 trades.

The stock hit an intraday high of Rs. 838.80 and intraday low of 795.00. The net turnover during the day was Rs. 374543.00.

Source : Equity Bulls

Keywords

ThemisMedicare INE083B01016 Approval DCGI VIRALEX